Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Bloom

Showing results (221-230 of 252) with videos related to

Pageof 26
Sort By:
British Journal of Clinical Pharmacology|November 3, 2010
The effects of kisspeptin-54 on blood pressure in humans and plasma kisspeptin concentrations in hypertensive diseases of pregnancyGurjinder M K Nijher, Owais B Chaudhri, Radha Ramachandran, et al.
Diabetes|June 19, 2014
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intakeJaimini Cegla, Rachel C Troke, Ben Jones, et al.
American Journal of Physiology. Endocrinology and Metabolism|January 18, 2021
Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover studyEmma Rose McGlone, Khalefah Malallah, Joyceline Cuenco, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2009
Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxisChanna N Jayasena, Gurjinder M K Nijher, Owais B Chaudhri, et al.
Molecular Metabolism|May 2, 2021
Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonistPhil Pickford, Maria Lucey, Roxana-Maria Rujan, et al.
Diabetes|December 19, 2012
Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemiaTricia M Tan, Benjamin C T Field, Katherine A McCullough, et al.
Diabetes, Obesity & Metabolism|January 17, 2024
Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trialDavid C D Hope, Saleem Ansari, Sirazum Choudhury, et al.
The Lancet. Diabetes & Endocrinology|June 9, 2019
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trialAlexander Dimitri Miras, Belén Pérez-Pevida, Madhawi Aldhwayan, et al.
Molecular Metabolism|September 5, 2024
Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in miceTatiana Lopes, David Cd Hope, Jose M Ramos-Pittol, et al.
Human Reproduction (Oxford, England)|September 1, 2017
A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trialAli Abbara, Sophie Clarke, Rumana Islam, et al.
Pageof 26

Showing results (221-230 of 252) with videos related to

Sort By:
Pageof 26
British Journal of Clinical Pharmacology|November 3, 2010
The effects of kisspeptin-54 on blood pressure in humans and plasma kisspeptin concentrations in hypertensive diseases of pregnancyGurjinder M K Nijher, Owais B Chaudhri, Radha Ramachandran, et al.
Diabetes|June 19, 2014
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intakeJaimini Cegla, Rachel C Troke, Ben Jones, et al.
American Journal of Physiology. Endocrinology and Metabolism|January 18, 2021
Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover studyEmma Rose McGlone, Khalefah Malallah, Joyceline Cuenco, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2009
Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxisChanna N Jayasena, Gurjinder M K Nijher, Owais B Chaudhri, et al.
Molecular Metabolism|May 2, 2021
Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonistPhil Pickford, Maria Lucey, Roxana-Maria Rujan, et al.
Diabetes|December 19, 2012
Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemiaTricia M Tan, Benjamin C T Field, Katherine A McCullough, et al.
Diabetes, Obesity & Metabolism|January 17, 2024
Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trialDavid C D Hope, Saleem Ansari, Sirazum Choudhury, et al.
The Lancet. Diabetes & Endocrinology|June 9, 2019
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trialAlexander Dimitri Miras, Belén Pérez-Pevida, Madhawi Aldhwayan, et al.
Molecular Metabolism|September 5, 2024
Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in miceTatiana Lopes, David Cd Hope, Jose M Ramos-Pittol, et al.
Human Reproduction (Oxford, England)|September 1, 2017
A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trialAli Abbara, Sophie Clarke, Rumana Islam, et al.
Pageof 26